Cargando…
Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study
AIMS: This bioequivalence study aimed to compare rate and extent of absorption of a generic medicinal product of ibandronic acid 150-mg film-coated tablet versus Bonviva(®). METHODS: This was a single-centre, open-label, randomized, three-way, three-sequence, reference-replicated, crossover bioequiv...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070455/ https://www.ncbi.nlm.nih.gov/pubmed/24756462 http://dx.doi.org/10.1007/s40268-014-0044-x |
_version_ | 1782322689846804480 |
---|---|
author | Filipe, Augusto Pedroso, Pedro Almeida, Susana Neves, Rita Boudreault, Sylvie |
author_facet | Filipe, Augusto Pedroso, Pedro Almeida, Susana Neves, Rita Boudreault, Sylvie |
author_sort | Filipe, Augusto |
collection | PubMed |
description | AIMS: This bioequivalence study aimed to compare rate and extent of absorption of a generic medicinal product of ibandronic acid 150-mg film-coated tablet versus Bonviva(®). METHODS: This was a single-centre, open-label, randomized, three-way, three-sequence, reference-replicated, crossover bioequivalence study, under fasting conditions. A single oral dose of ibandronic acid as one 150-mg film-coated tablet was administered in each study period. Each washout period lasted 14 days. Blood samples were collected according to a predefined sampling schedule and up to 48.0 hours after administraton in each period. Plasma concentrations of ibandronic acid were measured using a liquid chromatograph–mass spectrometry/mass spectrometry method. Bioequivalence between generic and reference medicinal products is acceptable if the 90 % confidence intervals (CI) of ratio of least-squares means between the test and the reference product of ln-transformed area under the serum concentration–time curve from time zero to time of last measurable concentration (AUC(0–t)) is within the 80.00–125.00 % interval. Prospectively, a scaled average bioequivalence approach for maximum serum concentration (C (max)) was established. RESULTS: 153 healthy volunteers were enrolled and randomized. After the test formulation (T) and first and second Bonviva(®) (R) dosing, the C (max) was 96.71 ± 90.19 ng/mL, 92.67 ± 91.48 ng/mL and 87.94 ± 60.20 ng/mL and the AUC(0–t) was 390.83 ± 287.27 ng·h/mL, 388.54 ± 356.76 ng·h/mL and 383.53 ± 246.72, respectively. Ratios of T/R and 90 % CI were 100.92 % (94.35–107.94) for AUC(0–t), 100.90 % (94.37–107.88) for AUC(0–inf) and 102.56 % (95.05–110.67) for C (max). CONCLUSIONS: Test formulation of ibandronic acid is bioequivalent in rate and extent of absorption to Bonviva(®) following a 150-mg dose, under fasting conditions. |
format | Online Article Text |
id | pubmed-4070455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-40704552014-07-16 Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study Filipe, Augusto Pedroso, Pedro Almeida, Susana Neves, Rita Boudreault, Sylvie Drugs R D Original Research Article AIMS: This bioequivalence study aimed to compare rate and extent of absorption of a generic medicinal product of ibandronic acid 150-mg film-coated tablet versus Bonviva(®). METHODS: This was a single-centre, open-label, randomized, three-way, three-sequence, reference-replicated, crossover bioequivalence study, under fasting conditions. A single oral dose of ibandronic acid as one 150-mg film-coated tablet was administered in each study period. Each washout period lasted 14 days. Blood samples were collected according to a predefined sampling schedule and up to 48.0 hours after administraton in each period. Plasma concentrations of ibandronic acid were measured using a liquid chromatograph–mass spectrometry/mass spectrometry method. Bioequivalence between generic and reference medicinal products is acceptable if the 90 % confidence intervals (CI) of ratio of least-squares means between the test and the reference product of ln-transformed area under the serum concentration–time curve from time zero to time of last measurable concentration (AUC(0–t)) is within the 80.00–125.00 % interval. Prospectively, a scaled average bioequivalence approach for maximum serum concentration (C (max)) was established. RESULTS: 153 healthy volunteers were enrolled and randomized. After the test formulation (T) and first and second Bonviva(®) (R) dosing, the C (max) was 96.71 ± 90.19 ng/mL, 92.67 ± 91.48 ng/mL and 87.94 ± 60.20 ng/mL and the AUC(0–t) was 390.83 ± 287.27 ng·h/mL, 388.54 ± 356.76 ng·h/mL and 383.53 ± 246.72, respectively. Ratios of T/R and 90 % CI were 100.92 % (94.35–107.94) for AUC(0–t), 100.90 % (94.37–107.88) for AUC(0–inf) and 102.56 % (95.05–110.67) for C (max). CONCLUSIONS: Test formulation of ibandronic acid is bioequivalent in rate and extent of absorption to Bonviva(®) following a 150-mg dose, under fasting conditions. Springer International Publishing 2014-04-23 2014-06 /pmc/articles/PMC4070455/ /pubmed/24756462 http://dx.doi.org/10.1007/s40268-014-0044-x Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Research Article Filipe, Augusto Pedroso, Pedro Almeida, Susana Neves, Rita Boudreault, Sylvie Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study |
title | Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study |
title_full | Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study |
title_fullStr | Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study |
title_full_unstemmed | Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study |
title_short | Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study |
title_sort | bioequivalence study of two formulations of ibandronic acid 150-mg film-coated tablets in healthy volunteers under fasting conditions: a randomized, open-label, three-way, reference-replicated crossover study |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070455/ https://www.ncbi.nlm.nih.gov/pubmed/24756462 http://dx.doi.org/10.1007/s40268-014-0044-x |
work_keys_str_mv | AT filipeaugusto bioequivalencestudyoftwoformulationsofibandronicacid150mgfilmcoatedtabletsinhealthyvolunteersunderfastingconditionsarandomizedopenlabelthreewayreferencereplicatedcrossoverstudy AT pedrosopedro bioequivalencestudyoftwoformulationsofibandronicacid150mgfilmcoatedtabletsinhealthyvolunteersunderfastingconditionsarandomizedopenlabelthreewayreferencereplicatedcrossoverstudy AT almeidasusana bioequivalencestudyoftwoformulationsofibandronicacid150mgfilmcoatedtabletsinhealthyvolunteersunderfastingconditionsarandomizedopenlabelthreewayreferencereplicatedcrossoverstudy AT nevesrita bioequivalencestudyoftwoformulationsofibandronicacid150mgfilmcoatedtabletsinhealthyvolunteersunderfastingconditionsarandomizedopenlabelthreewayreferencereplicatedcrossoverstudy AT boudreaultsylvie bioequivalencestudyoftwoformulationsofibandronicacid150mgfilmcoatedtabletsinhealthyvolunteersunderfastingconditionsarandomizedopenlabelthreewayreferencereplicatedcrossoverstudy |